Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker

Esther S. Oh, Christopher M. Marano, Jeannie Marie Leoutsakos, Rebecca W. Lee, Robert A. Rissman, Gwenn S. Smith, Suzanne Craft, Constantine G. Lyketsos

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Introduction: Plasma levels of amyloid-beta (Aβ) do not correlate well with different stages of Alzheimer's disease (AD) in cross-sectional studies. Measuring the changes in Aβ plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (mild cognitive impairment [MCI]) from normal controls. Methods: A total of 57 participants (18 with AD/MCI and 39 cognitively normal controls) underwent oral glucose tolerance testing (OGTT). Blood samples were obtained over a 2-hour period. Changes in plasma Aβ40 and 42 levels were measured from either baseline or 5 minutes to the 10-minute time-point. Results: Compared with normal controls, subjects with AD/MCI had significantly less change (δ) in plasma levels for both Aβ40 (-3.13 [40.93] vs. 41.34 pg/mL [57.16]; P = .002) and Aβ42 (-0.15 [3.77] vs. 5.64 pg/mL [10.65]; P = .004). Discussion: OGTT combined with measures of plasma Aβ40 and 42 is potentially useful in distinguishing aging individuals who are in different stages of AD.

Original languageEnglish (US)
Pages (from-to)311-315
Number of pages5
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Issue number3
StatePublished - Sep 1 2015


  • Alzheimer's disease
  • Blood biomarker
  • Oral glucose tolerance test

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker'. Together they form a unique fingerprint.

Cite this